Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirafugratinib in Previously Treated Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820Phase 2Recruiting
- Sponsor
- Elevar Therapeutics
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of lirafugratinib in solid tumor, sponsored by Elevar Therapeutics. Started Jun 2026; status: recruiting.
02
Drugs
lirafugratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07359820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359820.